Dovato (Dolutegravir/Lamivudine) Shortage: What Providers and Prescribers Need to Know in 2026

For HIV providers, the stakes of a missed or delayed antiretroviral refill are clear: viral rebound, resistance development, and potential clinical deterioration. While Dovato (dolutegravir/lamivudine) is not currently listed on the FDA's drug shortage database as of early 2026, real-world access barriers continue to create prescription fulfillment gaps that require proactive clinical management.

This clinical overview summarizes the current Dovato availability landscape, explains the root causes of access challenges, details appropriate clinical alternatives, and provides a practical workflow framework for your practice.

Current Dovato Availability Status (2026)

As of early 2026, Dovato (dolutegravir 50 mg/lamivudine 300 mg) is not listed on the FDA drug shortage database, nor on the ASHP drug shortage list. ViiV Healthcare reports no manufacturing disruptions. There is no evidence of supply chain failure at the national level.

However, at the pharmacy level, patients continue to encounter access barriers stemming from specialty drug distribution practices, insurance prior authorization requirements, and pharmacy stocking decisions. These barriers disproportionately affect patients who rely on retail chain pharmacies rather than HIV-specialty pharmacies.

Root Causes of Dovato Access Challenges

Understanding the reasons behind access challenges allows providers to take targeted steps. The primary drivers are:

• Specialty drug economics. At a retail price of approximately $2,000–$3,700 per 30-tablet supply, most retail pharmacies will not maintain standing inventory. They order on demand, resulting in 1–3 business day delays per refill cycle.
• No generic formulation. The fixed-dose Dovato tablet has no approved generic in the US as of 2026. Patent expiry is estimated around 2031. A single-manufacturer supply chain reduces flexibility.
• Prior authorization friction. Many commercial payers and some Medicaid programs require PA for Dovato. PA approval timelines vary widely by payer, ranging from same-day to 5+ business days. PA delays directly translate to adherence gaps.
• Biktarvy market dominance. Biktarvy accounts for the majority of HIV antiretroviral prescriptions in the US. Pharmacies that primarily serve Biktarvy patients may deprioritize or exclude Dovato from their standing inventory.

Clinical Implications of Treatment Interruption

Providers should counsel patients that interruptions in Dovato — even of 2–3 days — carry clinical risks:

• HIV viral rebound in patients who were previously undetectable
• Development of integrase resistance (INSTI resistance to dolutegravir is rare due to its high barrier to resistance, but not impossible under suboptimal conditions)
• In HBV co-infected patients: sudden HBV flare upon lamivudine discontinuation, including potential hepatic decompensation (Boxed Warning)

Clinical Alternatives When Dovato Cannot Be Obtained

When Dovato truly cannot be sourced, the following antiretroviral regimens should be considered on an individualized basis:

• Biktarvy (BIC/FTC/TAF): Widely available; once-daily; preferred for HBV co-infected patients. Most practical emergency alternative.
• Triumeq (DTG/ABC/3TC): Shares dolutegravir backbone; requires prior HLA-B*5701 screening; not for HBV co-infection.
• Juluca (DTG/RPV): For virologically suppressed adults; must be taken with food (≥500 kcal); contraindicated with PPIs.
• Cabenuva (CAB/RPV injectable): For suppressed patients preferring to eliminate daily oral therapy; requires clinic-based injections monthly or every 2 months.

Important reminder on HBV co-infection: Patients co-infected with HBV must have HBV coverage maintained through any regimen change. Do not leave patients without tenofovir-based HBV treatment if discontinuing Dovato.

Recommended Practice Workflows

To minimize Dovato access disruptions in your practice:

1. Identify 2–3 reliable Dovato pharmacies in your area (ideally at least one HIV specialty pharmacy) and share this list with your care team.
2. Submit PA proactively — before the patient needs their next refill, particularly for new starts or plan changes.
3. Maintain Dovato samples in your office supply when available from your ViiV Healthcare representative.
4. Enroll eligible patients in ViiV Connect (1-844-588-3288) at time of prescribing — this gives patients access to copay cards, pharmacy locators, and PA support.
5. Use medfinder for Providers to check real-time pharmacy inventory when writing or renewing Dovato prescriptions.

Savings and Patient Assistance Resources

Cost is also an access barrier. Share these programs with patients at the time of prescribing:

• ViiV Copay Savings Card: Commercially insured patients may pay as little as $0/month.
• ViiV Patient Assistance Program: Free drug for qualifying uninsured/underinsured patients (singles earning <$40,000/year may qualify).
• ADAP (AIDS Drug Assistance Program): State-administered program providing free or low-cost antiretrovirals including Dovato for eligible patients.

Summary for Providers

Dovato is not in a formal shortage, but proactive prescribing practices can prevent the distribution barriers from becoming patient adherence problems. Identify reliable pharmacy partners, submit PA proactively, maintain samples, and enroll patients in ViiV Connect support programs. For real-time pharmacy inventory verification, medfinder for Providers can help your team find Dovato stock in your area quickly and efficiently.